Put up against placebo in the phase 3 EMBARK trial, delandistrogene moxeparvovec (Elevidys) did not significantly improve ...

The SELECT-MDS-1 trial showed no significant complete response rate improvement with tamibarotene plus azacitidine for ...

Endpoint Detection and Response (EDR) firm Cybereason and managed security services provider (MSSP) Trustwave announced plans to merge.

Syros Pharmaceuticals announced that its phase 3 trial of tamibarotene in combination with azacitidine did not meet the primary endpoint for the treatment of myelodysplastic syndrome.

Merck KGaA said its cell-tumor treatment Pimicotinib met its primary endpoint in a late-stage trial. The German pharma company said Tuesday that its experimental drug showed significant improvement in ...

The Data Monitoring Committee (DMC) of the BHF-PROTECT-TAVI trial determined “there is little prospect of demonstrating a benefit in the primary endpoint.” Moreover, given the confidence intervals, ...

Shares of AbbVie (ABBV) are sliding on Monday after the company’s drug candidate for schizophrenia failed to meet the key goal in two ...

After the company said ‘all options are on the table,’ two experts say CISOs should prepare for a possible sale.

The latest VIPRE Endpoint EDR+MDR package empowers businesses with continuous expert incident response and a robust security ...

Johnson & Johnson’s CD38 inhibitor Darzalex showed a benefit in delaying or preventing disease progression in patients with ...

Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous ...

The best endpoint protection software provides an easy way to manage all of the devices within your business IT network, and keep them protected from malware and cyber attacks. To best protect a ...